Immix Biopharma is a biotech company that develops treatments for cancer and other inflammation-driven diseases.
Immix Biopharma has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
Immix Biopharma's investors include Mesa Verde Venture Partners, GOOSE Capital.
Immix Biopharma is headquartered in Los Angeles, United States.
Immix Biopharma is a biotech company that develops treatments for cancer and other inflammation-driven diseases.
Immix Biopharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Immix Biopharma — Funding & Investors." VCBacked, May 21, 2026, https://www.vcbacked.co/company/immix-biopharma. Accessed October 10, 2026.
VCBacked. (2026). Immix Biopharma — Funding & Investors. Retrieved October 10, 2026, from https://www.vcbacked.co/company/immix-biopharma
{{cite web |title=Immix Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/immix-biopharma |website=VCBacked |access-date=October 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated